Evidence map›Paper›PMID 32860615›Full record

ReviewJournal of gastrointestinal cancer2020

Malatya and Other Criteria for Liver Transplantation in Hepatocellular Carcinoma.

Volkan Ince, Cengiz Ara, Sezai Yilmaz

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of gastrointestinal cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Volkan InceDepartment of Surgery, Liver Transplantation Institute, Inonu University, 44315, Malatya, Turkey. volkanince@outlook.com.ORCID https://orcid.org/0000-0002-0714-490X
Cengiz AraDepartment of Surgery, Liver Transplantation Institute, Inonu University, 44315, Malatya, Turkey.ORCID https://orcid.org/0000-0002-6843-875X
Sezai YilmazDepartment of Surgery, Liver Transplantation Institute, Inonu University, 44315, Malatya, Turkey.ORCID https://orcid.org/0000-0002-8044-0297

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeLiver transplantation is a curative treatment option for hepatocellular carcinoma. In this review, we aimed to review liver transplantation criteria for hepatocellular carcinoma and patient survivals.

methodsWe reviewed literature in terms of liver transplant criteria for hepatocellular carcinoma. Patient eligibility criteria, post-transplant survivals, tumor recurrence and expansion of Milan criteria rates were analyzed.

resultsThe Milan criteria, after being published in 1996, have become for deceased donor liver transplantation in hepatocellular carcinoma worldwide. Later, many transplant centers published their own liver transplant criteria. Most of the criteria consisted of morphological tumor characteristics based on tumor size and number. The newest published one is Malatya criteria. The 5-year overall survival according the all of the criteria is greater than 50%. There were just one paper which compare criteria according to survival and Malatya criteria were the best amongst extended criteria with 5-year OS 79.7% in that study.

conclusionIt is clear that morphological criteria consisting only of tumor size and number are insufficient in patient selection for liver transplantation and should thus be combined with biological, inflammatory, radiological, pathological and genetic markers that predict the biological behavior of the tumor. Efforts to find the best criteria are still ongoing and 5-year overall survival should be greater than 60%.

Indexed as

Biomarkers, TumorCarcinoma, HepatocellularHumansLiverLiver CirrhosisLiver NeoplasmsLiver TransplantationNeoplasm Recurrence, LocalPatient SelectionRisk AssessmentSurvival RateTumor BurdenBiomarkers, TumorExpansion rateExtended criteriaLive donorLiver cancer

Identifiers

PMID32860615

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.